Suppr超能文献

夏洛特心肌梗死后 1 年的 ST 段抬高(STEMI HOC-1)研究:一项前瞻性研究方案。

ST-segment elevation myocardial infarction heart of Charlotte one-year (STEMI HOC-1) study: a prospective study protocol.

机构信息

Division of Cardiology, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, 2193, Johannesburg, South Africa.

出版信息

BMC Cardiovasc Disord. 2023 Aug 11;23(1):396. doi: 10.1186/s12872-023-03416-3.

Abstract

BACKGROUND

ST-segment elevation myocardial infarction (STEMI) is a clinically distinguishable yet lethal sequela of ischaemic heart disease (IHD). In sub-Saharan Africa (SSA), death due to acute STEMI is increasing. In South Africa, there is a paucity of data available on the clinical outcomes of acute STEMI within one year for individuals treated in the public healthcare sector. This study primarily seeks to determine the one-year all-cause mortality rate of acute STEMI. The study also assesses the value of serum cardiac biomarkers of myocardial damage and serum uric acid in predicting all-cause mortality in STEMI.

METHODS

This is a single-centre observational prospective cohort of all consecutive individuals presenting with an acute STEMI to the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in Johannesburg, South Africa. Research data will be sourced on admission through electronic medical records, blood laboratory results and coronary angiography reports, and at follow-up through periodic telephonic interviews and standardised echocardiograms. At least 355 eligible participants will be continuously followed over one year, and clinical outcomes will be measured 30 days, three months, six months and one year after the index hospitalisation.

DISCUSSION

This study provides insights into the demographic, risk factors and clinical profiles of individuals with STEMI in South Africa. Its findings may improve the risk stratification, prognostication, and therapeutic management of STEMI patients in our setting. By comparing the clinical outcomes between the different coronary reperfusion strategies, our results may guide clinicians in providing better patient treatment, particularly in sub-Saharan Africa, where access to percutaneous coronary intervention may be limited. Furthermore, the study offers insights into the routine use of baseline serum uric acid as a potential low-cost prognostic biomarker of all-cause mortality in STEMI. Finally, this study's findings may be of public health significance to local policymakers to aid in reinforcing primary prevention strategies and developing structured referral networks for timely coronary reperfusion of acute STEMI.

摘要

背景

ST 段抬高型心肌梗死(STEMI)是一种可临床区分但具有致命性的缺血性心脏病(IHD)后遗症。在撒哈拉以南非洲(SSA),急性 STEMI 导致的死亡人数正在增加。在南非,公共医疗保健部门治疗的急性 STEMI 患者在一年内的临床结局数据非常有限。本研究主要旨在确定急性 STEMI 的一年全因死亡率。该研究还评估了血清心肌损伤标志物和血清尿酸在预测 STEMI 全因死亡率方面的价值。

方法

这是一项在南非约翰内斯堡夏洛特·马克斯凯 Johannesburg 学术医院(CMJAH)连续入组所有急性 STEMI 患者的单中心观察性前瞻性队列研究。研究数据将通过电子病历、血液实验室结果和冠状动脉造影报告在入院时获取,并通过定期电话访谈和标准超声心动图在随访时获取。至少有 355 名符合条件的参与者将在一年内连续随访,在指数住院后 30 天、3 个月、6 个月和 1 年时测量临床结局。

讨论

本研究提供了有关南非 STEMI 患者的人口统计学、风险因素和临床特征的见解。其研究结果可能会改善我们治疗环境中 STEMI 患者的风险分层、预后和治疗管理。通过比较不同的冠状动脉再灌注策略的临床结局,我们的结果可能会指导临床医生为患者提供更好的治疗,特别是在经皮冠状动脉介入治疗可能受限的撒哈拉以南非洲。此外,该研究还提供了关于基线血清尿酸作为 STEMI 全因死亡率潜在低成本预后生物标志物的常规使用的见解。最后,本研究的结果可能对当地政策制定者具有公共卫生意义,有助于加强初级预防策略并为急性 STEMI 的及时冠状动脉再灌注建立结构化转诊网络。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验